Search

Your search keyword '"Hachulla, E"' showing total 3,216 results
Start Over Author "Hachulla, E"
3,216 results on '"Hachulla, E"'

3. French National Diagnostic and Care Protocol for antiphospholipid syndrome in adults and children

Author

Chauveau, D., Clouscard, J., Frere, C., Hachulla, E., Kone-Paut, I., Lasne, D., Lecompte, T., Le Guern, V., Ni Zard, J., Papo, T., Riviere, M., Schleinitz, N., Tossier, B., Amoura, Z., Bader-Meunier, B., BAL dit Sollier, C., Belot, A., Benhamou, Y., Bezanahary, H., Cohen, F., Costedoat-Chalumeau, N., Darnige, L., Drouet, L., Elefant, E., Harroche, A., Lambert, M., Martin, T., Martin-Toutain, I., Mathian, A., Mekinian, A., Pineton De Chambrun, M., de Pontual, L., Wahl, D., Yelnik, C., and Zuily, S.

Published
2023
Full Text
View/download PDF

7. Atteinte musculaire au cours de la sclérodermie systémique : la mortalité n’est pas associée à la nature des lésions histologiques

Author

Le Gouellec, N., primary, Zaidan, L., additional, Chaigne, B., additional, Periou, B., additional, Cailliau, E., additional, Dhôte, R., additional, Riviere, S., additional, Uzunhan, Y., additional, Agard, C., additional, Godeau, B., additional, Wolkenstein, P., additional, Hachulla, E., additional, Mouthon, L., additional, and Authier, J., additional

Published
2024
Full Text
View/download PDF

9. POS0235 NEW ONSET OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: CLINICAL COURSE AND OUTCOMES FROM A EUSTAR DATABASE ANALYSIS

Author

Bruni, C., primary, Petelytska, L., additional, Velauthapillai, A., additional, Tofani, L., additional, Carreira, P., additional, Cuomo, G., additional, Hachulla, E., additional, Castellví, I., additional, Bečvář, R., additional, Balbir-Gurman, A., additional, Airò, P., additional, Litinsky, I., additional, Saketkoo, L. A., additional, De Vries-Bouwstra, J. K., additional, Vonk, M., additional, Hoffmann-Vold, A. M., additional, Matucci-Cerinic, M., additional, and Distler, O., additional

Published
2024
Full Text
View/download PDF

10. POS1258 STRATIFICATION OF SJÖGREN’S DISEASE, BASED ON SYMPTOMS, CLINICAL AND ROUTINE BIOLOGICAL DATA, IS SUPPORTED BY DISTINCT PATHOPHYSIOLOGICAL PATHWAYS

Author

Nguyen, Y., primary, Mariette, X., additional, Beydon, M., additional, Cornec, D., additional, Pers, J. O., additional, Morel, J., additional, Perdriger, A., additional, Dernis, E., additional, Devauchelle-Pensec, V., additional, Sene, D., additional, Dieudé, P., additional, Couderc, M., additional, Fauchais, A. L., additional, Larroche, C., additional, Vittecoq, O., additional, Salliot, C., additional, Hachulla, E., additional, Le Guern, V., additional, Gottenberg, J. E., additional, Seror, R., additional, and Nocturne, G., additional

Published
2024
Full Text
View/download PDF

11. POS0211 PAH TREATMENT AT TIME OF DIAGNOSIS IS ASSOCIATED WITH IMPROVED SURVIVAL REGARDLESS OF HEMODYNAMIC THRESHOLDS AND RISK STRATIFICATION - A EUSTAR ANALYSIS

Author

Bjørkekjær, H. J., primary, Bruni, C., additional, Brunborg, C., additional, Carreira, P., additional, Airò, P., additional, Simeón-Aznar, C. P., additional, Truchetet, M. E., additional, Giollo, A., additional, Balbir-Gurman, A., additional, Martin, M., additional, Denton, C. P., additional, Gabrielli, A., additional, Fretheim, H., additional, Bitter, H., additional, Midtvedt, Ø., additional, Broch, K., additional, Andreassen, A., additional, Høie, S., additional, Tanaka, Y., additional, Riemekasten, G., additional, Müller-Ladner, U., additional, Matucci-Cerinic, M., additional, Castellví, I., additional, Siegert, E., additional, Hachulla, E., additional, Molberg, Ø., additional, Distler, O., additional, and Hoffmann-Vold, A. M., additional

Published
2024
Full Text
View/download PDF

12. POS1263 LYMPHOMA TREATMENT STRATEGY AFFECTS AUTOIMMUNE DISEASE ACTIVITY AND LYMPHOMA RELAPSE IN PATIENTS WITH SJÖGREN DISEASE AND MARGINAL ZONE LYMPHOMA

Author

Beydon, M., primary, Rocca, J., additional, Le Guern, V., additional, Hachulla, E., additional, Couderc, M., additional, Jousse-Joulin, S., additional, Devauchelle-Pensec, V., additional, Gottenberg, J. E., additional, Vittecoq, O., additional, Lavigne, C., additional, Schmidt, J., additional, Larroche, C., additional, Mariette, X., additional, Seror, R., additional, and Nocturne, G., additional

Published
2024
Full Text
View/download PDF

13. AB1251 PROGNOSIS OF ESSENTIAL MIXED CRYOGLOBULINEMIA AND CONNECTIVE TISSUE DISEASE-RELATED CRYOGLOBULINEMIA AFTER RITUXIMAB-INDUCED REMISSION

Author

Poggi, C., primary, Hachulla, E., additional, Karras, A., additional, Briantais, A., additional, Ravaiau, C., additional, Gobert, P., additional, Deroux, A., additional, Nicolas, S., additional, François, H., additional, Groh, M., additional, London, J., additional, Campagne, J., additional, Allain, J. S., additional, Dernis, E., additional, Durel, C. A., additional, Le Gallou, T., additional, Curie, A., additional, Kerschen, P., additional, Gensous, N., additional, Reboux, A. H., additional, Béhal, H., additional, Terrier, B., additional, and Quéméneur, T., additional

Published
2024
Full Text
View/download PDF

14. Prévalence et phénotype associé aux anticorps anti-Ro52-kDa/SSA (TRIM21) dans la sclérodermie systémique : données d’une cohorte française, revue de la littérature et méta-analyse

Author

Martel, M.E., primary, Leurs, A., additional, Launay, D., additional, Béhal, H., additional, Chepy, A., additional, Collet, A., additional, Sanges, S., additional, Hachulla, E., additional, Dubucquoi, S., additional, Dauchet, L., additional, and Sobanski, V., additional

Published
2024
Full Text
View/download PDF

15. POS0700 SEVERE ENTEROVIRUS INFECTIONS IN PATIENTS WITH AUTOIMMUNE DISEASES RECEIVING ANTI-CD20 MONOCLONAL ANTIBODIES

Author

Martin de Frémont, G., primary, Chabrolles, H., additional, Mirand, A., additional, L’honneur, A. S., additional, Mele, N., additional, Boutboul, D., additional, Farhat, M., additional, Hachulla, E., additional, Lazrek, M., additional, Rieu, V., additional, Mathian, A., additional, Chaussade, H., additional, Ruet, A., additional, Burrel, S., additional, Coury-Lucas, F., additional, Schuffenecker, I., additional, Lemaignen, A., additional, Stefic, K., additional, Le Besnerais, M., additional, Carrette, M., additional, Mouthon, L., additional, Avettand-Fenoel, V., additional, Terrier, B., additional, and Hadjadj, J., additional

Published
2024
Full Text
View/download PDF

16. OP0225 CHANGES IN TREATMENT PATTERNS AND THEIR INFLUENCE ON THE OUTCOME OF SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE (SSc-ILD) PATIENTS: AN EUSTAR ANALYSIS

Author

Campochiaro, C., primary, Truchetet, M. E., additional, Vonk, M., additional, Cuomo, G., additional, Ananyeva, L. P., additional, Hachulla, E., additional, Smith, V., additional, Gheorghiu, A. M., additional, Bečvář, R., additional, Carreira, P., additional, Hunzelmann, N., additional, Furst, D., additional, Ortiz-Santamaria, V., additional, Del Galdo, F., additional, Matucci-Cerinic, M., additional, and Hoffmann-Vold, A. M., additional

Published
2024
Full Text
View/download PDF

20. OP0289 PREVALENCE OF ANTI-RO52-KDA/SSA (TRIM21) ANTIBODIES AND ASSOCIATED CLINICAL PHENOTYPE IN SYSTEMIC SCLEROSIS: DATA FROM A FRENCH COHORT, A SYSTEMATIC REVIEW AND META-ANALYSIS

Author

Martel, M. E., primary, Leurs, A., additional, Launay, D., additional, Béhal, H., additional, Chepy, A., additional, Collet, A., additional, Sanges, S., additional, Hachulla, E., additional, Dubucquoi, S., additional, Dauchet, L., additional, and Sobanski, V., additional

Published
2024
Full Text
View/download PDF

23. Impact of Risk Factors on COVID-19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID-19 Global Rheumatology Alliance Registry

Author

Yazdany, J, Ware, A, Wallace, Z, Bhana, S, Grainger, R, Hachulla, E, Richez, C, Cacoub, P, Hausmann, J, Liew, J, Sirotich, E, Jacobsohn, L, Strangfeld, A, Mateus, E, Hyrich, K, Gossec, L, Carmona, L, Lawson-Tovey, S, Kearsley-Fleet, L, Schaefer, M, Ribeiro, S, Al-Emadi, S, Hasseli, R, Müller-Ladner, U, Specker, C, Schulze-Koops, H, Bernardes, M, Fraga, V, Rodrigues, A, Sparks, J, Ljung, L, Di Giuseppe, D, Tidblad, L, Wise, L, Duarte-García, A, Ugarte-Gil, M, Colunga-Pedraza, I, Martínez-Martínez, M, Alpizar-Rodriguez, D, Xavier, R, Isnardi, C, Pera, M, Pons-Estel, G, Izadi, Z, Gianfrancesco, M, Carrara, G, Scirè, C, Zanetti, A, Machado, P, Wallace, ZS, Hausmann, JS, Liew, JW, Mateus, EF, Hyrich, KL, Ribeiro, SLE, Fraga, VM, Rodrigues, AM, Sparks, JA, Ugarte-Gil, MF, Colunga-Pedraza, IJ, Martínez-Martínez, MU, Xavier, RM, Isnardi, CA, Gianfrancesco, MA, Scirè, CA, Machado, PM, Yazdany, J, Ware, A, Wallace, Z, Bhana, S, Grainger, R, Hachulla, E, Richez, C, Cacoub, P, Hausmann, J, Liew, J, Sirotich, E, Jacobsohn, L, Strangfeld, A, Mateus, E, Hyrich, K, Gossec, L, Carmona, L, Lawson-Tovey, S, Kearsley-Fleet, L, Schaefer, M, Ribeiro, S, Al-Emadi, S, Hasseli, R, Müller-Ladner, U, Specker, C, Schulze-Koops, H, Bernardes, M, Fraga, V, Rodrigues, A, Sparks, J, Ljung, L, Di Giuseppe, D, Tidblad, L, Wise, L, Duarte-García, A, Ugarte-Gil, M, Colunga-Pedraza, I, Martínez-Martínez, M, Alpizar-Rodriguez, D, Xavier, R, Isnardi, C, Pera, M, Pons-Estel, G, Izadi, Z, Gianfrancesco, M, Carrara, G, Scirè, C, Zanetti, A, Machado, P, Wallace, ZS, Hausmann, JS, Liew, JW, Mateus, EF, Hyrich, KL, Ribeiro, SLE, Fraga, VM, Rodrigues, AM, Sparks, JA, Ugarte-Gil, MF, Colunga-Pedraza, IJ, Martínez-Martínez, MU, Xavier, RM, Isnardi, CA, Gianfrancesco, MA, Scirè, CA, and Machado, PM

Abstract

Objective: Approximately one third of individuals worldwide have not received a COVID-19 vaccine. Although studies have investigated risk factors linked to severe COVID-19 among unvaccinated people with rheumatic diseases (RDs), we know less about whether these factors changed as the pandemic progressed. We aimed to identify risk factors associated with severe COVID-19 in unvaccinated individuals in different pandemic epochs corresponding to major variants of concern. Methods: Patients with RDs and COVID-19 were entered into the COVID-19 Global Rheumatology Alliance Registry between March 2020 and June 2022. An ordinal logistic regression model (not hospitalized, hospitalized, and death) was used with date of COVID-19 diagnosis, age, sex, race and/or ethnicity, comorbidities, RD activity, medications, and the human development index (HDI) as covariates. The main analysis included all unvaccinated patients across COVID-19 pandemic epochs; subanalyses stratified patients according to RD types. Results: Among 19,256 unvaccinated people with RDs and COVID-19, those who were older, male, had more comorbidities, used glucocorticoids, had higher disease activity, or lived in lower HDI regions had worse outcomes across epochs. For those with rheumatoid arthritis, sulfasalazine and B-cell–depleting therapy were associated with worse outcomes, and tumor necrosis factor inhibitors were associated with improved outcomes. In those with connective tissue disease or vasculitis, B-cell–depleting therapy was associated with worse outcomes. Conclusion: Risk factors for severe COVID-19 outcomes were similar throughout pandemic epochs in unvaccinated people with RDs. Ongoing efforts, including vaccination, are needed to reduce COVID-19 severity in this population, particularly in those with medical and social vulnerabilities identified in this study.

Published
2024

24. Syndrome des antiphospholipides et hémorragie intra-alvéolaire : une étude française multicentrique et rétrospective

Author

Ramos, M., primary, Yelnik, C., additional, De Antonio, M., additional, Viallard, J., additional, Hachulla, E., additional, Ruivard, M., additional, Le Guenno, G., additional, André, M., additional, Milesi Lecat, A., additional, Trouillier, S., additional, Samson, M., additional, Lavigne, C., additional, Lebreton, A., additional, Lambert, M., additional, Costedoat-Chalumeau, N., additional, and Grobost, V., additional

Published
2024
Full Text
View/download PDF

25. Étude nationale multicentrique sur l’utilisation du NINTEDANIB en vie réelle dans la PID-SSc

Author

Koether, V., primary, Launay, D., additional, Reynaud, M., additional, Prevot, G., additional, Mouthon, L., additional, Borie, R., additional, Husseini, K. El, additional, Decker, P., additional, Dirou, S., additional, Blanchard, E., additional, Leurs, A., additional, Berthier, S., additional, Delbrel, X., additional, Durel, M., additional, Agard, C., additional, Nievez-Martinez, A., additional, Hachulla, E., additional, Aydindag, D., additional, Cottin, V., additional, and Uzunhan, Y., additional

Published
2024
Full Text
View/download PDF

27. Tolérance et efficacité des thérapies ciblées prescrites pour des indications hors AMM dans les maladies auto-immunes systémiques réfractaires : données des 187 premiers patients inclus dans le registre TATA (TArgeted Therapy in Autoimmune Diseases)

Author

Gottenberg, J.E., primary, Kane, B.S., additional, Allenbach, Y., additional, Mékinian, A., additional, Amoura, Z., additional, Cacoub, P., additional, Cornec, D., additional, Hachulla, E., additional, Quartier, P., additional, Richez, C., additional, Seror, R., additional, Terrier, B., additional, Pensec, V. Devauchelle, additional, Henry, J., additional, Gatfosse, M., additional, Bouillet, L., additional, Gaigneux, E., additional, André, V., additional, Saunier, A., additional, Desmurs, M., additional, Poulet, A., additional, Bienvenu, B., additional, Truchetet, M.E., additional, Michaud, M., additional, Larroche, C., additional, Dellal, A., additional, Leurs, A., additional, Ottaviani, S., additional, Nielly, H., additional, Vial, G., additional, Jaussaud, R., additional, Rouviere, B., additional, Jeandel, C., additional, Guffroy, A., additional, Jouvray, M., additional, Gramont, B., additional, Lavigne, C., additional, Marotte, H., additional, Moulinet, T., additional, Pers, Y., additional, Queyrel-Moranne, V., additional, Maalouf, G., additional, Bolko, L., additional, Rein, C., additional, Legendre, P., additional, Meyer, A., additional, Sibilia, J., additional, Yahia, S. Ahmed, additional, Kleinmann, J.F., additional, and Mariette, X., additional

Published
2023
Full Text
View/download PDF

28. Trajectoire d’ouverture buccale dans la sclérodermie systémique : une analyse longitudinale de 1101 patients issus de la cohorte française nationale

Author

Chaigne, B., primary, Bense, A., additional, Agard, C., additional, Allanore, Y., additional, Pugnet, G., additional, Hachulla, E., additional, Avouac, J., additional, Bienvenu, B., additional, Palat, S., additional, Grange, C., additional, Berthier, S., additional, Chatelus, E., additional, Riviere, S., additional, Truchetet, M.E., additional, Jean, E.K., additional, Maurier, F., additional, Diot, E., additional, Berezne, A., additional, and Mouthon, L., additional

Published
2023
Full Text
View/download PDF

29. Présentation clinique, évolution et pronostic des patients atteints de connectivite mixte : une cohorte rétrospective multicentrique

Author

Chevalier, K., primary, Thoreau, B., additional, Michel, M., additional, Godeau, B., additional, Agard, C., additional, Papo, T., additional, Seror, R., additional, Samson, M., additional, Ackermann, F., additional, Lambotte, O., additional, Mariette, X., additional, Cacoub, P., additional, Benhamou, Y., additional, Levesque, H., additional, Goujard, C., additional, Bonnotte, B., additional, Schmidt, J., additional, Hachulla, E., additional, Chaigne, B., additional, and Mouthon, L., additional

Published
2023
Full Text
View/download PDF

30. Détermination de trois phénotypes distincts de la maladie de Sjögren associés à des pronostics différents par une analyse de cluster basée sur les manifestations cliniques et biologiques : données des cohortes Paris-Saclay et ASSESS

Author

Nguyen, Y., primary, Nocturne, G., additional, Henry, J., additional, Ng, W.F., additional, Belkhir, R., additional, Desmoulins, F., additional, Bergé, E., additional, Morel, J., additional, Perdriger, A., additional, Dernis, E., additional, Pensec, V. Devauchelle, additional, Sene, D., additional, Dieudé, P., additional, Couderc, M., additional, Fauchais, A.L., additional, Larroche, C., additional, Vittecoq, O., additional, Salliot, C., additional, Hachulla, E., additional, Le Gern, V., additional, Gottenberg, J.E., additional, Mariette, X., additional, and Seror, R., additional

Published
2023
Full Text
View/download PDF

31. Cibler ccr4 avec le mogamulizumab dans le syndrome hyperéosinophilique réfractaire de variant lymphoïde CD3–CD4+

Author

Ledoult, E., primary, Groh, M., additional, Meresse, B., additional, Dubois, R., additional, Trauet, J., additional, Toussaint, E., additional, Delbeke, M., additional, Hachulla, E., additional, Terriou, L., additional, De Masson, A., additional, Labalette, M., additional, Launay, D., additional, Kahn, J.E., additional, and Lefèvre, G., additional

Published
2023
Full Text
View/download PDF

33. Les lymphomes compliquant la maladie de Sjögren sont associés à une accumulation de variations génétiques germinales sur des voies favorisant l’hyper-activation lymphocytaire B

Author

Nocturne, G., primary, Jabot-Hanin, F., additional, Gottenberg, J.E., additional, Hachulla, E., additional, Le Gern, V., additional, Lenoir, C., additional, Larroche, C., additional, Olivier, V., additional, Saraux, A., additional, Latour, S., additional, and Mariette, X., additional

Published
2023
Full Text
View/download PDF

35. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research

Author

Hoffmann-Vold A. -M., Brunborg C., Airo P., Ananyeva L. P., Czirjak L., Guiducci S., Hachulla E., Li M., Mihai C., Riemekasten G., Sfikakis P. P., Valentini G., Kowal-Bielecka O., Allanore Y., Distler O., Vacca A., Giollo A., Balbir-Gurman A., Gheorghiu A. M., Marcoccia A., Herrick A., Radic M., Stamenkovic B., Anic B., Granel B., Ribi C., Selmi C. F., Carlos de la Puente M., de Souza Muller C., Denton C., Kayser C., Tanaseanu C. -M., Majewski D., Rimar D., Krasowska D., Veale D., Walker U., Kerzberg E., Rezus E., Zanatta E., Siegert E., De Langhe E., Oksel F., Ingegnoli F., Cantatore F. P., Szucs G., Cuomo G., Seskute G., Litinsky V., Castellvi I., Morovic-Vergles J., Sibilia J., Henes J., Solanki K., Perdan-Pirkmajer K., Herrmann K., Saketkoo L. A., Stamp L., Mouthon L., Salvador M. J., Pozzi M. R., Uprus M., Vanthuyne M., Engelhart M., Kohm M., Iudici M., Inanc M., Fathi N., Pamuk N., Garcia de la Pena Lefebv P., Carreira P. E., Bancel D. F., Moroncini L., Montecucco C., Ancuta C., Sunderkotter C., Muller-Ladner U., Rosato E., Kucharz E. J., Iannone F., Del Galdo F., Poormoghim H., Kotter I., Distler J., Cutolo M., Tikly M., Damjanov N., Hunzelmann N., Vlachoyiannopoulos P., Hasler P., Sarzi Puttini P., Wiland P., Becvar R., Yavuz S., Zdrojewski Z., Pellerito R., Foti R., Ionescu R. M., Adler S., Kahl S., Moiseev S., Stebbings S., Rednic S., Negrini S., Heitmann S., Ullman S., Agachi S., Martin T., Schmeiser T., Riccieri V., Smith V., Bernardino V., Ortiz-Santamaria V., Hsu V. M., Abdel Atty Mohamed W. A., Hoffmann-Vold, A. -M., Brunborg, C., Airo, P., Ananyeva, L. P., Czirjak, L., Guiducci, S., Hachulla, E., Li, M., Mihai, C., Riemekasten, G., Sfikakis, P. P., Valentini, G., Kowal-Bielecka, O., Allanore, Y., Distler, O., Vacca, A., Giollo, A., Balbir-Gurman, A., Gheorghiu, A. M., Marcoccia, A., Herrick, A., Radic, M., Stamenkovic, B., Anic, B., Granel, B., Ribi, C., Selmi, C. F., Carlos de la Puente, M., de Souza Muller, C., Denton, C., Kayser, C., Tanaseanu, C. -M., Majewski, D., Rimar, D., Krasowska, D., Veale, D., Walker, U., Kerzberg, E., Rezus, E., Zanatta, E., Siegert, E., De Langhe, E., Oksel, F., Ingegnoli, F., Cantatore, F. P., Szucs, G., Cuomo, G., Seskute, G., Litinsky, V., Castellvi, I., Morovic-Vergles, J., Sibilia, J., Henes, J., Solanki, K., Perdan-Pirkmajer, K., Herrmann, K., Saketkoo, L. A., Stamp, L., Mouthon, L., Salvador, M. J., Pozzi, M. R., Uprus, M., Vanthuyne, M., Engelhart, M., Kohm, M., Iudici, M., Inanc, M., Fathi, N., Pamuk, N., Garcia de la Pena Lefebv, P., Carreira, P. E., Bancel, D. F., Moroncini, L., Montecucco, C., Ancuta, C., Sunderkotter, C., Muller-Ladner, U., Rosato, E., Kucharz, E. J., Iannone, F., Del Galdo, F., Poormoghim, H., Kotter, I., Distler, J., Cutolo, M., Tikly, M., Damjanov, N., Hunzelmann, N., Vlachoyiannopoulos, P., Hasler, P., Sarzi Puttini, P., Wiland, P., Becvar, R., Yavuz, S., Zdrojewski, Z., Pellerito, R., Foti, R., Ionescu, R. M., Adler, S., Kahl, S., Moiseev, S., Stebbings, S., Rednic, S., Negrini, S., Heitmann, S., Ullman, S., Agachi, S., Martin, T., Schmeiser, T., Riccieri, V., Smith, V., Bernardino, V., Ortiz-Santamaria, V., Hsu, V. M., and Abdel Atty Mohamed, W. A.

Subjects
interstitial lung disease, Pulmonary and Respiratory Medicine, enrichment, systemic sclerosis, clinical trial, Cardiology and Cardiovascular Medicine, Critical Care and Intensive Care Medicine
Abstract

BACKGROUND: Enrichment strategies from clinical trials for progressive systemic sclerosis-associated interstitial lung disease (SSc-ILD) have not been tested in a real-life cohort.RESEARCH QUESTION: Do enrichment strategies for progressive ILD impact efficacy, repre-sentativeness, and feasibility in patients with SSc-ILD from the European Scleroderma Trials and Research (EUSTAR) database?STUDY DESIGN AND METHODS: We applied the inclusion criteria of major recent SSc-ILD trials (Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis [focuSSced], Scleroderma Lung Study II [SLS II], and Safety and Efficacy of Nintedanib in Systemic Sclerosis [SENSCIS]) and assessed progressive ILD, which was defined as absolute change in FVC and as significant progression (FVC decline $10%). Data were compared with all patients and with patients who did not fulfill any inclusion criteria. RESULTS: In total, 2,258 patients with SSc-ILD were included: 31.2% of the patients met SENSCIS criteria; 5.8% of the patients met SLS II criteria; 1.6% of the patients met focuSSced criteria, and 67.7% (1,529) of the patients did not meet any criteria. In the first 12 + 3 months, the absolute FVC decline in all patients and in patients who fulfilled criteria from SENSCIS was -0.1%, in patients who fulfilled criteria from focuSSced was -3.7%, and in patients who fulfilled criteria from SLS II was 2.3%, with accompanying more progressors in focuSSced. The patient populations that fulfilled the different study inclusion criteria significantly differed in various clinical parameters. In the second 12-month period, SENSCIS-enriched patients had a further absolute FVC% decline as described for the total cohort. In contrast, patients who fulfilled the focuSSced and SLS II criteria showed numeric improvement of lung function. There were no significant associations of enrichment criteria and ILD progression.INTERPRETATION: The application of enrichment criteria from previous clinical trials showed enrichment for progression with variable success, which led to selected patient populations reducing feasibility of recruitment. These findings are important for future clinical trial design and interpretation of the results of published trials.CHEST 2023; 163(3):586-598

Published
2023

36. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

Author

Talarico, R, Ramirez, G, Barreira, S, Cardamone, C, Triggianese, P, Aguilera, S, Andersen, J, Avcin, T, Benistan, K, Bertsias, G, Bortoluzzi, A, Bouillot, C, Bulina, I, Burmester, G, Callens, S, Carreira, P, Cervera, R, Cutolo, M, Damian, L, Della-Torre, E, Faria, R, Fonseca, J, Galetti, I, Hachulla, E, Iaccarino, L, Jacobsen, S, Khmelinskii, N, Limper, M, Marinello, D, Meyer, A, Moroncini, G, Nagy, G, Olesinska, M, Pamfil, C, Pileckyte, M, Pistello, M, Rednic, S, Richez, C, Romao, V, Schneider, M, Sciascia, S, Scire, C, Simonini, G, Smith, V, Sulli, A, Tani, C, Tas, S, Tincani, A, Vonk, M, Tektonidou, M, Mosca, M, Talarico R., Ramirez G. A., Barreira S. C., Cardamone C., Triggianese P., Aguilera S., Andersen J., Avcin T., Benistan K., Bertsias G., Bortoluzzi A., Bouillot C., Bulina I., Burmester G. R., Callens S., Carreira P. E., Cervera R., Cutolo M., Damian L., Della-Torre E., Faria R., Fonseca J. E., Galetti I., Hachulla E., Iaccarino L., Jacobsen S., Khmelinskii N., Limper M., Marinello D., Meyer A., Moroncini G., Nagy G., Olesinska M., Pamfil C., Pileckyte M., Pistello M., Rednic S., Richez C., Romao V. C., Schneider M., Sciascia S., Scire C. A., Simonini G., Smith V., Sulli A., Tani C., Tas S. W., Tincani A., Vonk M. C., Tektonidou M., Mosca M., Talarico, R, Ramirez, G, Barreira, S, Cardamone, C, Triggianese, P, Aguilera, S, Andersen, J, Avcin, T, Benistan, K, Bertsias, G, Bortoluzzi, A, Bouillot, C, Bulina, I, Burmester, G, Callens, S, Carreira, P, Cervera, R, Cutolo, M, Damian, L, Della-Torre, E, Faria, R, Fonseca, J, Galetti, I, Hachulla, E, Iaccarino, L, Jacobsen, S, Khmelinskii, N, Limper, M, Marinello, D, Meyer, A, Moroncini, G, Nagy, G, Olesinska, M, Pamfil, C, Pileckyte, M, Pistello, M, Rednic, S, Richez, C, Romao, V, Schneider, M, Sciascia, S, Scire, C, Simonini, G, Smith, V, Sulli, A, Tani, C, Tas, S, Tincani, A, Vonk, M, Tektonidou, M, Mosca, M, Talarico R., Ramirez G. A., Barreira S. C., Cardamone C., Triggianese P., Aguilera S., Andersen J., Avcin T., Benistan K., Bertsias G., Bortoluzzi A., Bouillot C., Bulina I., Burmester G. R., Callens S., Carreira P. E., Cervera R., Cutolo M., Damian L., Della-Torre E., Faria R., Fonseca J. E., Galetti I., Hachulla E., Iaccarino L., Jacobsen S., Khmelinskii N., Limper M., Marinello D., Meyer A., Moroncini G., Nagy G., Olesinska M., Pamfil C., Pileckyte M., Pistello M., Rednic S., Richez C., Romao V. C., Schneider M., Sciascia S., Scire C. A., Simonini G., Smith V., Sulli A., Tani C., Tas S. W., Tincani A., Vonk M. C., Tektonidou M., and Mosca M.

Abstract

Recent studies have shown that people who are immunocompromised may inadvertently play a role in spurring the mutations of the virus that create new variants. This is because some immunocompromised individuals remain at risk of getting COVID-19 despite vaccination, experience more severe disease, are susceptible to being chronically infected and remain contagious for longer if they become infected and considering that immunocompromised individuals represent approximately 2% of the overall population, this aspect should be carefully considered. So far, some autoimmune rheumatic disease (ARD) patients with COVID-19 have been treated with antiviral therapies or anti-SARS-CoV-2 antibody products. However, there is no homogeneous approach to these treatment strategies. This issue was addressed within the European Reference Network (ERN) on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ReCONNET) in a discussion among experts and patient's representatives in the context of the rare and complex connective tissue diseases (rCTDs) covered by the Network. ERN ReCONNET is one of the 24 ERNs launched by the European Commission in 2017 with the aim of tackling low prevalence and rare diseases that require highly specialised treatment and promoting concentration of knowledge and resources through virtual networks involving healthcare providers (HCPs) across the European Union (EU). Considering the urgent need to provide guidance not only to the rCTDs community, but also to the whole ARDs community, a multidisciplinary Task Force, including expert clinicians and European Patient Advocacy Group (ePAG) Advocates, was created in the framework of ERN ReCONNET with the aim of developing overarching principles (OP) and points-to-consider (PtC) on a homogenous approach to treat immunocompromised patients with ARDs (with a particular focus on CTDs) affected by COVID-19 using antiviral therapies and anti-SARS-CoV-2 antibody products. The present work reports the final OP

Published
2023

40. French National Diagnostic and Care Protocol for antiphospholipid syndrome in adults and children

Author

Amoura, Z., primary, Bader-Meunier, B., additional, BAL dit Sollier, C., additional, Belot, A., additional, Benhamou, Y., additional, Bezanahary, H., additional, Cohen, F., additional, Costedoat-Chalumeau, N., additional, Darnige, L., additional, Drouet, L., additional, Elefant, E., additional, Harroche, A., additional, Lambert, M., additional, Martin, T., additional, Martin-Toutain, I., additional, Mathian, A., additional, Mekinian, A., additional, Pineton De Chambrun, M., additional, de Pontual, L., additional, Wahl, D., additional, Yelnik, C., additional, Zuily, S., additional, Chauveau, D., additional, Clouscard, J., additional, Frere, C., additional, Hachulla, E., additional, Kone-Paut, I., additional, Lasne, D., additional, Lecompte, T., additional, Le Guern, V., additional, Ni Zard, J., additional, Papo, T., additional, Riviere, M., additional, Schleinitz, N., additional, and Tossier, B., additional

Published
2023
Full Text
View/download PDF

41. Infections sévères à entérovirus chez les patients traités par rituximab pour une maladie auto-immune : série de cas et revue de la littérature

Author

Frémont, G. Martin de, primary, Mirand, A., additional, L’honneur, A.S., additional, Dunogué, B., additional, Boutboul, D., additional, Farhat, M.M., additional, Hachulla, E., additional, Lazrek, M., additional, Rieu, V., additional, Mathian, A., additional, Chaussade, H., additional, Burrel, S., additional, Desclaux, A., additional, Ruet, A., additional, Lemaignen, A., additional, Le Besnerais, M., additional, Coury, F., additional, Mouthon, L., additional, Terrier, B., additional, and Hadjadj, J., additional

Published
2023
Full Text
View/download PDF

43. Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Author

Yeoh, S, Gianfrancesco, M, Lawson-Tovey, S, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Schafer, M, Richez, C, Hachulla, E, Holmqvist, M, Scire, C, Lorenz, H, Voll, R, Hasseli, R, Jayatilleke, A, Hsu, T, D'Silva, K, Pimentel-Quiroz, V, Vasquez Del Mercado, M, Shinjo, S, Neto, E, Junior, L, De Oliveira E Silva Montandon, A, Pons-Estel, G, Ornella, S, D'Angelo Exeni, M, Velozo, E, Jordan, P, Sirotich, E, Hausmann, J, Liew, J, Jacobsohn, L, Gore-Massy, M, Sufka, P, Grainger, R, Bhana, S, Wallace, Z, Robinson, P, Yazdany, J, Machado, P, Yeoh S. -A., Gianfrancesco M., Lawson-Tovey S., Hyrich K. L., Strangfeld A., Gossec L., Carmona L., Mateus E. F., Schafer M., Richez C., Hachulla E., Holmqvist M., Scire C. A., Lorenz H. -M., Voll R. E., Hasseli R., Jayatilleke A., Hsu T. Y. -T., D'Silva K. M., Pimentel-Quiroz V. R., Vasquez Del Mercado M., Shinjo S. K., Neto E. T. D. R., Junior L. F. D. R., De Oliveira E Silva Montandon A. C., Pons-Estel G. J., Ornella S., D'Angelo Exeni M. E., Velozo E., Jordan P., Sirotich E., Hausmann J. S., Liew J. W., Jacobsohn L., Gore-Massy M., Sufka P., Grainger R., Bhana S., Wallace Z., Robinson P. C., Yazdany J., MacHado P. M., Yeoh, S, Gianfrancesco, M, Lawson-Tovey, S, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Schafer, M, Richez, C, Hachulla, E, Holmqvist, M, Scire, C, Lorenz, H, Voll, R, Hasseli, R, Jayatilleke, A, Hsu, T, D'Silva, K, Pimentel-Quiroz, V, Vasquez Del Mercado, M, Shinjo, S, Neto, E, Junior, L, De Oliveira E Silva Montandon, A, Pons-Estel, G, Ornella, S, D'Angelo Exeni, M, Velozo, E, Jordan, P, Sirotich, E, Hausmann, J, Liew, J, Jacobsohn, L, Gore-Massy, M, Sufka, P, Grainger, R, Bhana, S, Wallace, Z, Robinson, P, Yazdany, J, Machado, P, Yeoh S. -A., Gianfrancesco M., Lawson-Tovey S., Hyrich K. L., Strangfeld A., Gossec L., Carmona L., Mateus E. F., Schafer M., Richez C., Hachulla E., Holmqvist M., Scire C. A., Lorenz H. -M., Voll R. E., Hasseli R., Jayatilleke A., Hsu T. Y. -T., D'Silva K. M., Pimentel-Quiroz V. R., Vasquez Del Mercado M., Shinjo S. K., Neto E. T. D. R., Junior L. F. D. R., De Oliveira E Silva Montandon A. C., Pons-Estel G. J., Ornella S., D'Angelo Exeni M. E., Velozo E., Jordan P., Sirotich E., Hausmann J. S., Liew J. W., Jacobsohn L., Gore-Massy M., Sufka P., Grainger R., Bhana S., Wallace Z., Robinson P. C., Yazdany J., and MacHado P. M.

Abstract

Objectives To investigate factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy (IIM). Methods Demographic data, clinical characteristics and COVID-19 outcome severity of adults with IIM were obtained from the COVID-19 Global Rheumatology Alliance physician-reported registry. A 3-point ordinal COVID-19 severity scale was defined: (1) no hospitalisation, (2) hospitalisation (and no death) and (3) death. ORs were estimated using multivariable ordinal logistic regression. Sensitivity analyses were performed using a 4-point ordinal scale: (1) no hospitalisation, (2) hospitalisation with no oxygen (and no death), (3) hospitalisation with oxygen/ventilation (and no death) and 4) death. Results Of 348 patients, 48% were not hospitalised, 39% were hospitalised (and did not die) and 13% died. Older age (OR=1.59/decade, 95% CI 1.31 to 1.91), high disease activity (OR=3.50, 95% CI 1.25 to 9.83; vs remission), ≥2 comorbidities (OR=2.63, 95% CI 1.39 to 4.98; vs none), prednisolone-equivalent dose >7.5 mg/day (OR=2.40, 95% CI 1.09 to 5.28; vs no intake) and exposure to rituximab (OR=2.71, 95% CI 1.28 to 5.72; vs conventional synthetic disease-modifying antirheumatic drugs only) were independently associated with severe COVID-19. In addition to these variables, in the sensitivity analyses, male sex (OR range: 1.65-1.83; vs female) was also significantly associated with severe outcomes, while COVID-19 diagnosis after 1 October 2020 (OR range: 0.51-0.59; vs on/before 15 June 2020) was significantly associated with less severe outcomes, but these associations were not significant in the main model (OR=1.57, 95% CI 0.95 to 2.59; and OR=0.61, 95% CI 0.37 to 1.00; respectively). Conclusions This is the first large registry data on outcomes of COVID-19 in people with IIM. Older age, male sex, higher comorbidity burden, high disease activity, prednisolone-equivalent dose >7.5 mg/day and rituximab exposure were associated with severe COVID-19. These

Published
2022

44. The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET

Author

Talarico, R, Aguilera, S, Alexander, T, Amoura, Z, Andersen, J, Arnaud, L, Avcin, T, Marsal Barril, S, Beretta, L, Bombardieri, S, Bortoluzzi, A, Bouillot, C, Bulina, I, Burmester, G, Cannizzo, S, Cavagna, L, Chaigne, B, Cornet, A, Corti, P, Costedoat-Chalumeau, N, Davidsone, Z, Doria, A, Fenech, C, Ferraris, A, Fischer-Betz, R, Fonseca, J, Frank, C, Gaglioti, A, Galetti, I, Guimaraes, V, Hachulla, E, Holmner, M, Houssiau, F, Iaccarino, L, Jacobsen, S, Limper, M, Malfait, F, Mariette, X, Marinello, D, Martin, T, Matthews, L, Matucci-Cerinic, M, Meyer, A, Milas-Ahic, J, Moinzadeh, P, Montecucco, C, Mouthon, L, Muller-Ladner, U, Nagy, G, Patarata, E, Pileckyte, M, Pruunsild, C, Rednic, S, Romao, V, Schneider, M, Scire, C, Smith, V, Sulli, A, Tamirou, F, Tani, C, Taruscio, D, Taulaigo, A, Tincani, A, Ticciati, S, Turchetti, G, van Hagen, P, van Laar, J, Vieira, A, de Vries-Bouwstra, J, Zschocke, J, Cutolo, M, Mosca, M, Talarico R., Aguilera S., Alexander T., Amoura Z., Andersen J., Arnaud L., Avcin T., Marsal Barril S., Beretta L., Bombardieri S., Bortoluzzi A., Bouillot C., Bulina I., Burmester G. R., Cannizzo S., Cavagna L., Chaigne B., Cornet A., Corti P., Costedoat-Chalumeau N., Davidsone Z., Doria A., Fenech C., Ferraris A., Fischer-Betz R., Fonseca J. E., Frank C., Gaglioti A., Galetti I., Guimaraes V., Hachulla E., Holmner M., Houssiau F., Iaccarino L., Jacobsen S., Limper M., Malfait F., Mariette X., Marinello D., Martin T., Matthews L., Matucci-Cerinic M., Meyer A., Milas-Ahic J., Moinzadeh P., Montecucco C., Mouthon L., Muller-Ladner U., Nagy G., Patarata E., Pileckyte M., Pruunsild C., Rednic S., Romao V. C., Schneider M., Scire C. A., Smith V., Sulli A., Tamirou F., Tani C., Taruscio D., Taulaigo A. V., Tincani A., Ticciati S., Turchetti G., van Hagen P. M., van Laar J. M., Vieira A., de Vries-Bouwstra J. K., Zschocke J., Cutolo M., Mosca M., Talarico, R, Aguilera, S, Alexander, T, Amoura, Z, Andersen, J, Arnaud, L, Avcin, T, Marsal Barril, S, Beretta, L, Bombardieri, S, Bortoluzzi, A, Bouillot, C, Bulina, I, Burmester, G, Cannizzo, S, Cavagna, L, Chaigne, B, Cornet, A, Corti, P, Costedoat-Chalumeau, N, Davidsone, Z, Doria, A, Fenech, C, Ferraris, A, Fischer-Betz, R, Fonseca, J, Frank, C, Gaglioti, A, Galetti, I, Guimaraes, V, Hachulla, E, Holmner, M, Houssiau, F, Iaccarino, L, Jacobsen, S, Limper, M, Malfait, F, Mariette, X, Marinello, D, Martin, T, Matthews, L, Matucci-Cerinic, M, Meyer, A, Milas-Ahic, J, Moinzadeh, P, Montecucco, C, Mouthon, L, Muller-Ladner, U, Nagy, G, Patarata, E, Pileckyte, M, Pruunsild, C, Rednic, S, Romao, V, Schneider, M, Scire, C, Smith, V, Sulli, A, Tamirou, F, Tani, C, Taruscio, D, Taulaigo, A, Tincani, A, Ticciati, S, Turchetti, G, van Hagen, P, van Laar, J, Vieira, A, de Vries-Bouwstra, J, Zschocke, J, Cutolo, M, Mosca, M, Talarico R., Aguilera S., Alexander T., Amoura Z., Andersen J., Arnaud L., Avcin T., Marsal Barril S., Beretta L., Bombardieri S., Bortoluzzi A., Bouillot C., Bulina I., Burmester G. R., Cannizzo S., Cavagna L., Chaigne B., Cornet A., Corti P., Costedoat-Chalumeau N., Davidsone Z., Doria A., Fenech C., Ferraris A., Fischer-Betz R., Fonseca J. E., Frank C., Gaglioti A., Galetti I., Guimaraes V., Hachulla E., Holmner M., Houssiau F., Iaccarino L., Jacobsen S., Limper M., Malfait F., Mariette X., Marinello D., Martin T., Matthews L., Matucci-Cerinic M., Meyer A., Milas-Ahic J., Moinzadeh P., Montecucco C., Mouthon L., Muller-Ladner U., Nagy G., Patarata E., Pileckyte M., Pruunsild C., Rednic S., Romao V. C., Schneider M., Scire C. A., Smith V., Sulli A., Tamirou F., Tani C., Taruscio D., Taulaigo A. V., Tincani A., Ticciati S., Turchetti G., van Hagen P. M., van Laar J. M., Vieira A., de Vries-Bouwstra J. K., Zschocke J., Cutolo M., and Mosca M.

Abstract

In order to address the main challenges related to the rare diseases (RDs) the European Commission launched the European Reference Networks (ERNs), virtual networks involving healthcare providers (HCPs) across Europe. The mission of the ERNs is to tackle low prevalence and RDs that require highly specialised treatment and a concentration of knowledge and resources. In fact, ERNs offer the potential to give patients and healthcare professionals across the EU access to the best expertise and timely exchange of lifesaving knowledge, trying to make the knowledge travelling more than patients. For this reason, ERNs were established as concrete European infrastructures, and this is particularly crucial in the framework of rare and complex diseases in which no country alone has the whole knowledge and capacity to treat all types of patients. It has been five years since their kick-off launch in Vilnius in 2017. The 24 ERNs have been intensively working on different transversal areas, including patient management, education, clinical practice guidelines, patients' care pathways and many other fundamental topics. The present work is therefore aimed not only at reporting a summary of the main activities and milestones reached so far, but also at celebrating the first 5 years of the ERN on Rare and Complex Connective Tissue and Musculo-skeletal Diseases (ReCONNET), in which the members of the network built together one of the 24 infrastructures that are hopefully going to change the scenario of rare diseases across the EU.

Published
2022

45. OP0238 IMMUNOSUPPRESSION WITH TARGETED DMARDS REDUCES MORBIDITY AND MORTALITY IN PRE-CAPILLARY PULMONARY HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: A EUSTAR ANALYSIS

Author

Bruni, C., primary, Tofani, L., additional, Fretheim, H., additional, Weber, Y., additional, Hachulla, E., additional, Carreira, P., additional, Giuggioli, D., additional, Airò, P., additional, Siegert, E., additional, Müller-Ladner, U., additional, Matucci-Cerinic, M., additional, Riemekasten, G., additional, Simeon Aznar, C. P., additional, De Vries-Bouwstra, J., additional, Saketkoo, L. A., additional, Distler, J., additional, Balbir-Gurman, A., additional, Castellví, I., additional, Zanatta, E., additional, Smith, V., additional, Denton, C. P., additional, Maurer, B., additional, Giollo, A., additional, Iannone, F., additional, Dagna, L., additional, Truchetet, M. E., additional, Kuwana, M., additional, Allanore, Y., additional, Tanaka, Y., additional, Martin, M., additional, Rosato, E., additional, Gheorghiu, A. M., additional, Del Galdo, F., additional, Solanki, K., additional, Vacca, A., additional, Resende, C., additional, Vieira, S., additional, Czirják, L., additional, Baresic, M., additional, Cantatore, F. P., additional, Riccieri, V., additional, Andréasson, K., additional, Chung, L., additional, Souza Muller, C., additional, Opris-Belinski, D., additional, Rednic, S., additional, Sfikakis, P., additional, Levy, Y., additional, Hsu, V., additional, Heitmann, S., additional, Henes, J., additional, Moroncini, G., additional, Iudici, M., additional, De Langhe, E., additional, Herrick, A., additional, Montecucco, C., additional, Hoffmann-Vold, A. M., additional, and Distler, O., additional

Published
2023
Full Text
View/download PDF

46. POS1283 HEART AND SYSTEMIC SCLEROSIS – FINDINGS FROM NATIONAL COHORT STUDY

Author

Guedon, A. F., primary, Carrat, F., additional, Mouthon, L., additional, Launay, D., additional, Chaigne, B., additional, Pugnet, G., additional, Lega, J. C., additional, Hot, A., additional, Dhote, R., additional, Papo, T., additional, Chatelus, E., additional, Bonnotte, B., additional, Kahn, J. E., additional, Diot, E., additional, Bienvenu, B., additional, Magy-Bertrand, N., additional, Queyrel, V., additional, Le Quellec, A., additional, Kieffer, P., additional, Amoura, Z., additional, Harlé, J. R., additional, Cottin, V., additional, Gaultier, J. B., additional, Balquet, M. H., additional, Wahl, D., additional, Lidove, O., additional, Fauchais, A. L., additional, Allanore, Y., additional, Jégo, P., additional, Agard, C., additional, Fain, O., additional, Mekinian, A., additional, Hachulla, E., additional, and Riviere, S., additional

Published
2023
Full Text
View/download PDF

48. POS0164 CHARACTERIZATION OF PULMONARY MANIFESTATIONS OF SJÖGREN SYNDROME: A MULTICENTER RETROSPECTIVE STUDY

Author

Meudec, L., primary, Marques, C., additional, Juge, P. A., additional, Dhote, R., additional, Fauchais, A. L., additional, Dernis, E., additional, Vittecoq, O., additional, Saraux, A., additional, Gottenberg, J. E., additional, Hachulla, E., additional, Le Guern, V., additional, Dieudé, P., additional, Debray, M. P., additional, Beurnier, A., additional, Mariette, X., additional, Seror, R., additional, and Nocturne, G., additional

Published
2023
Full Text
View/download PDF

49. POS1454 ARE ULTRASOUND SALIVARY PARENCHYMAL ABNORMALITIES MORE SEVERE IN PRIMARY SJÖGREN PATIENTS WITH A HIGHER DISEASE DURATION? A TRANSVERSAL INTERNATIONAL STUDY

Author

Tison, A., primary, Jousse-Joulin, S., additional, Consigny, M., additional, Moog, P., additional, Hofauer, B., additional, Hachulla, E., additional, Lamotte, C., additional, Morel, J., additional, Mouterde, G., additional, Milic, V., additional, Bootsma, H., additional, Stel, A. J., additional, Fisher, B. A., additional, Maybury, M., additional, Baer, A., additional, Direnzo, D., additional, Kim, H. R., additional, Min, H. K., additional, Lee, S. S., additional, Choi, S. E., additional, Carvajal Alegria, G., additional, Boisramé, S., additional, Guellec, D., additional, Cornec, D., additional, Jonsson, M., additional, Hammenfors, D., additional, Saraux, A., additional, and Devauchelle-Pensec, V., additional

Published
2023
Full Text
View/download PDF

50. OP0233 IMPACT OF LYMPHOMA TREATMENT STRATEGY ON HEMATOLOGIC RESPONSE AND AUTOIMMUNE DISEASE ACTIVITY IN SJOGREN PATIENTS DEVELOPING LYMPHOMA

Author

Rocca, J., primary, Beydon, M., additional, Le Guern, V., additional, Hachulla, E., additional, Dubost, J. J., additional, Jousse-Joulin, S., additional, Devauchelle-Pensec, V., additional, Gottenberg, J. E., additional, Vittecoq, O., additional, Lavigne, C., additional, Schmidt, J., additional, Marcelli, C., additional, Larroche, C., additional, Mariette, X., additional, Seror, R., additional, and Nocturne, G., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results